Regulacje i polityka gospodarcza · 22/12/2015

National Institute of Drug Abuse to Grant Exclusive Start-Up Option License to EncepHeal Therapeutics for Monamine Transporter Technology

The National Institute of Drug Abuse, part of the National Institutes of Health, Department of Health and Human Services, is considering granting an exclusive start-up option license to EncepHeal Therapeutics, Inc., a biotech company based in Winston-Salem, North Carolina, for the development of potent and selective analogues of monamine transporters, as outlined in patent applications.